Renin: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: {{subpages}} '''Renin''' is a "highly specific (Leu-Leu) endopeptidase that generates angiotensin I from its precursor angiotensinogen, leading to a cascade of reactions which elevate ...) |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Renin''' is a "highly specific (Leu-Leu) endopeptidase that generates [[angiotensin]] I from its precursor angiotensinogen, leading to a cascade of reactions which elevate [[blood pressure]] and increase sodium retention by the kidney in the [[renin-angiotensin system]]."<ref>{{MeSH}}</ref> | '''Renin''' is a "highly specific (Leu-Leu) endopeptidase that generates [[angiotensin]] I from its precursor angiotensinogen, leading to a cascade of reactions which elevate [[blood pressure]] and increase sodium retention by the kidney in the [[renin-angiotensin system]]."<ref>{{MeSH}}</ref> | ||
Aliskiren is an oral direct renin inhibitor that according to a [[randomized controlled trial]] may have "renoprotective effects that are independent of its blood-pressure-lowering effect in patients with [[hypertension]], [[Diabetes mellitus type 2|type 2 diabetes]], and nephropathy."<ref name="pmid18525041">{{cite journal |author=Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK |title=Aliskiren combined with losartan in type 2 diabetes and nephropathy |journal=N. Engl. J. Med. |volume=358 |issue=23 |pages=2433–46 |year=2008 |month=June |pmid=18525041 |doi=10.1056/NEJMoa0708379 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18525041&promo=ONFLNS19 |issn=}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 01:22, 15 June 2008
Renin is a "highly specific (Leu-Leu) endopeptidase that generates angiotensin I from its precursor angiotensinogen, leading to a cascade of reactions which elevate blood pressure and increase sodium retention by the kidney in the renin-angiotensin system."[1]
Aliskiren is an oral direct renin inhibitor that according to a randomized controlled trial may have "renoprotective effects that are independent of its blood-pressure-lowering effect in patients with hypertension, type 2 diabetes, and nephropathy."[2]
References
- ↑ Anonymous (2024), Renin (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK (June 2008). "Aliskiren combined with losartan in type 2 diabetes and nephropathy". N. Engl. J. Med. 358 (23): 2433–46. DOI:10.1056/NEJMoa0708379. PMID 18525041. Research Blogging.